MRI Screening for Prostate Cancer

N/A

Recruiting

Led By Scott Eggener, MD

Research Sponsored by University of Chicago

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up every 3 years up to 15 years

Awards & highlights

No Placebo-Only Group

Summary

This trial will test if MRI can spot prostate cancer earlier in high-risk men.

Who is the study for?

This trial is for men aged 18 and older who are at high risk of developing prostate cancer but have no known history of it. They should not have had any previous prostate surgery or a biopsy within the last three years, nor an MRI in that time frame. Men with metal fragments, severe claustrophobia, without a rectum, or those who've had hip replacement are excluded.

What is being tested?

The study is testing if using Magnetic Resonance Imaging (MRI) can detect serious types of prostate cancer earlier and more reliably in men considered to be at high risk for this disease.

What are the potential side effects?

Since the intervention involves MRI screening, there may be discomfort due to lying still during the procedure. There's also a small chance of an allergic reaction to contrast materials if used. Claustrophobic individuals might experience anxiety.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ every 3 years up to 15 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~every 3 years up to 15 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and every 3 years up to 15 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Malignant Neoplasms

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

4Treatment groups

Experimental Treatment

Group I: Low Risk (n=125):Experimental Treatment1 Intervention

No known germline mutation, low genetic risk score (GRS \<1.5), and no known family history of prostate cancer.

Group II: High Risk- Positive Germline Mutation (n=40):Experimental Treatment1 Intervention

Men who harbor known germline mutations that have been associated with an increased risk of prostate cancer and aggressive disease (e.g. BRCA2, ATM, PALB2, etc.) with or without a known family history of prostate cancer.

Group III: High Risk- High GRS (n=40):Experimental Treatment1 Intervention

Men who harbor significantly increased disease risk based upon genetic risk score (GRS) value \>1.5 with or without a known family history of prostate cancer.

Group IV: High Risk- Family History (n=45):Experimental Treatment1 Intervention

Men with a family history of prostate cancer in at least one sibling, father, uncle, or grandfather but no known increased genetic risk of prostate cancer (has no pathogenic or likely pathogenic mutation along with a low genetic risk score (GRS\<1.5).

Do I qualify?Apply below to find out